Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Aluminum – calcium or magnesium element – or compound containing
Patent
1995-05-25
1997-11-04
Pak, John
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Aluminum, calcium or magnesium element, or compound containing
424682, 424709, A61K 3304, A61K 3306
Patent
active
056837259
ABSTRACT:
Modulation of substance P by compounds containing calcium sulfate is disclosed. Preferred calcium sulfate compounds include syngenite, gorgeyite and gypsum. Methods of this invention include the modulation of substance P, as well as methods for preventing or treating conditions associated with substance P, by administering to an animal an effective amount of a calcium sulfate compound. Conditions associated with substance P include headaches and migraine, neurogenic inflammation, emesis, nausea and vomiting, cough and bronchitis, obesity, allergy, asthma, hemorrhoids and anal fissures, ulcer, fever, infertility and periodontal disease.
REFERENCES:
patent: 4554139 (1985-11-01), Worthington et al.
patent: 4689223 (1987-08-01), Arias
patent: 4735802 (1988-04-01), Le
patent: 4915936 (1990-04-01), Patterson et al.
Derwent Abstracts, Accession No. 96-246881 C25, 1996, Abstracting JP 8099848 (Apr. 16, 1996).
Bartold et al., "Substance P: An Immunohistochemical and Biochemical Study in Human Gingival Tissues. A Role for Neurogenic Inflammation?," J. Periodontol 65:1113-1121 (1994).
Gyorfi et al., "Role of substance P (SP) in development of symptoms of neurogenic inflammation in the oral mucosa of the rat," J. Periodont Res 28:191-196 (1993).
Joos et al., "Sensory neuropeptides and the human lower airways: present state and future directions," Eur. Respir. J. 7:1161-1171 (1994).
Sestini et al., "Ion Transport in Rat Tracheal Epithelium In Vitro. Role of Capsaicin-sensitive Nerves in Allergic Reactions," AM Rev Respir 141:393-397 (1990).
Nakai et al., "Substance P-induced cutaneous and bronchial reactions in children with bronchial asthma," Ann. Allergy 66:155-161 (1991).
Hagiwara et al., "Studies on Neurokinin Antagonists. 4. Synthesis and Structure-Activity Relationships of Novel Dipeptide Substance P Antagonists: N.sup.2 -(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and Its Related Compounds." J. Med. Chem. 37:2090-2099 (1994).
Wallengren, J., "Substance P antagonist inhibits immediate and delayed type cutaneous hypersensitivity reactions," Br. J Derm. 124:324-328 (1991).
Felten et al., "Fundamental Aspects of Neural-Immune Signaling," Psycother. Psychosom. 60:46-56 (1993).
Lee et al., "Blockade by Oral or Parenteral RPR 100893 (a non-peptide NK.sub.1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva," Br. J. Pharmacol. 112:920-924 (1994).
Liu et al., "The effects of capsaicin on pulpal blood flow," Proc. Finn. Dent. Soc. 88(Supp. I):463-467 (1992).
Nieber et al., "The Possible Role of Substance P in the Allergic Reaction, Based on Two Different Provocation Models," Int. Arch. Allergy Appl. Immunol. 94:334-338 (1991).
Okamoto et al., "Cytokine Expression After the Topical Administration of Substance P to Human Nasal Mucosa. The Role of Substance P in Nasal Allergy," J. Immunol. 151:4391-4398 (1993).
Rameshwar et al., "In Vitro Stimulatory Effect of Substance P on Hematopoiesis." Blood 81:391-398 (1993).
Alleva et al., "Capsaicin Affects Aggressive Behavior, But Not Hot Plate Responding, of Adult Male Mice," Physiology & Behavior 49:715-719 (1991).
Crimi et al., "Influence of antihistamine (astemizole) and anticholinergic drugs (ipratropium bromide) on bronchoconstriction induced by substance P," Ann. Allergy 65:115-120 (1990).
Elliot et al., "Modulation of the rat mesolimbic dopamine pathway by neurokinins," Behavioural Brain Research 51:77-82 (1992).
Evangelista et al., "Duodenal SP-like immunoreactivity is decreased in experimentally-induced duodenal ulcers," Neuroscience Letters 112:352-355 (1990).
Malek-Ahmadi, P., "Substance P and Neuropsychiatric Disorders: An Overview," Neuroscience and Biobehavioral Reviews 16:365-369 (1992).
Moore & Black, "Neuropeptides," Neurosurg. Rev. 14:97-110 (1991).
Moussaoui et al., "Inhibition of neurogenic inflammation in the meninges by a non-peptide NK.sub.1 Receptor Antagonist, RP 67580," Eur. J. Pharma. 238:421-424 (1993).
Shuster, S., "Capsaicin and the cause of causalgia," Lancet 345:160-161 (1995).
Tsuji and Cook, "Origin of thromboxane-mediated constriction due to neuropeptides in canine basilar artery," Eur. J Pharma. 264:77-80 (1994).
Dockray, G., "Substance P and Other Tachykinins," in Gut Peptides: Biochemistry and Physiology, Raven Press, New York, N.Y. 1994 (edited by John Walsh and Graham Dockray), pp. 401-422.
Dryden et al., "Neuropeptide Y and energy balance: one way ahead for the treatment of obesity?" Eur. J Clin. Invest. 24:293-308 (1994).
Paus et al., "Hair Growth Induction by Substance P," Lab. Invest. 71:134-140 (1994).
Talley et al., "GR 38032F (Ondansetron), A Selective 5HT.sub.3 Receptor Antagonist, Slows Colonic Transit in Healthy Man," Digestive Diseases and Sciences 35:477-480 (1990).
Karlberg, B., "Cough and inhibition of the renin-angiotensin system," Journal of Hypertension 11(supp.3):S49-S52 (1993).
Blatteis, "Role of the OVLT in the febrile response to circulating pyrogens," Progress in Brain Research 91:409-412 (1992).
Nadel, J., "Mechanisms of Inflammation and Potential Role in the Pathogenesis of Asthma," Allergy Proc. 12:85-88 (1991).
Williams et al., "Reduced Hypothalamic Neurotensin Concentrations in the Genetically Obese Diabetic (ob/ob) Mouse: Possible Relationship to Obesity," Metabolism 40:1112-1116 (1991).
Blatteis et al., "Neuromodulation of Fever. A Possible Role for Substance P," Ann. N.Y. Acad. Sci. 741:162-173 (1992).
Gyorfi et al., "Neurogenic inflammation and the oral mucosa," J. Clin Periodontol 19:731-736 (1992).
Ohkubo et al., "Role of Substance P in Neurogenic Inflammation in the Rat Incisor Pulp and the Lower Lip," Archs oral Biol. 38:151-158 (1993).
Schmid et al., "Temperature sensitivity of neurons in slices of the rat PO/AH area: effect of bombesin and substance P," Am. J. Physiol. 264:R449-R455 (1993).
Barnes, R., "Neurogenic Inflammation and Asthma," Journal of Asthma 29:165-180 (1992).
Mosimann et al., "Allergens, IgE, mediators, inflammatory mechanisms. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients," J Allergy Clin Immunol 92:95-104 (1993).
Debeljuk and Bartke, "Immunoreactive Substance P and Neurokinin A in the Hypothalamus and Anterior Pituitary Gland of Siberian and Syrian Hamsters and of Rats," J Reproduction and Fertility 101:427-434 (1994).
Chiwakata et al., "Tachykinin (Substance-P) Gene Expression in Leydig Cells of the Human and Mouse Testis," Endocrinology 128:2441-2448 (1991).
Kerdelhue et al., "Hypothalamo-Anterior Pituitary Gonadotropin-Releasing Hormone and Substance-P Systems during the 17.beta.-Estradiol-Induced Plasma Luteinizing Hormone Surge in the Ovariectomized Female Monkey," Endocrinology 132:1151-1157 (1993).
Hebert Rolland F.
Malik Sohail
Yee Min
BioFrontiers, Inc.
Pak John
LandOfFree
Modulation of substance P by compounds containing calcium sulfat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of substance P by compounds containing calcium sulfat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of substance P by compounds containing calcium sulfat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1831181